Pricing Log in Create free account
Friday 6 November 2026 Export GRAL’s income statement to Excel — free account

GRAIL, Inc.

GRAL Healthcare Diagnostics & Research

GRAIL, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $147.2 million, up 17.2% from fiscal 2024.

Revenue
+3.71%
EPS
+10.2%
Free cash flow
−24.9%

Quarter to September 2026, against a year earlier

127.00 7.87 +6.61%
Market cap
$5.3B
P/E
0.0×
Fwd P/E
−14.5×
Dividend yield
—
F-score
6/9
Altman Z
0.37
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

GRAIL, Inc. (GRAL) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
10-Q Sep 30, 2026 P1I2: 9 added · 6 removed · 35 modified
P2I1A: 10 added · 1 removed · 3 modified 		Short cash runway Share dilution
8-K Nov 4, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2026 P1I2: 23 added · 8 removed · 32 modified
P2I1A: no comparison — the earlier filing's Item cannot be compared
8-K Aug 5, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jun 18, 2026 5.07 Submission of matters to a vote of security holders
8-K Jun 1, 2026 5.02 Departure or appointment of directors or officers; 8.01 Other events; 9.01 Financial statements and exhibits Officer departure
10-Q Mar 31, 2026
8-K May 5, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 69 added · 25 removed · 109 modified
1A: 45 added · 18 removed · 169 modified
7: 36 added · 32 removed · 70 modified
8-K Feb 19, 2026 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Jan 12, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Nov 13, 2025 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025
8-K Nov 12, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Oct 18, 2025 1.01 Entry into a material definitive agreement; 3.02 Unregistered sales of equity securities; 9.01 Financial statements and exhibits
8-K Oct 16, 2025 1.01 Entry into a material definitive agreement; 2.02 Results of operations and financial condition; 3.02 Unregistered sales of equity securities; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Sep 11, 2025 1.01 Entry into a material definitive agreement; 2.03 Creation of a direct financial obligation; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
8-K Aug 12, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Mar 31, 2025
8-K May 13, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2024 Impairment
8-K Feb 20, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 15, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 30, 2024
8-K Nov 12, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024
8-K Aug 13, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.